伊班膦酸治疗肺癌骨转移痛疗效及安全性分析  

Efficiency and safety of ibandronate in the treatment of metastatic bone pain induced by lung cancer

作　　者：许勇飞[1] 邓文英[1] 李宁[1] 罗素霞[1] 

机构地区：[1]郑州大学附属肿瘤医院(河南省肿瘤医院)内科,河南郑州450008

出　　处：《现代肿瘤医学》2015年第3期351-353,共3页Journal of Modern Oncology

摘　　要：目的:对比分析首剂负荷剂量及常规剂量伊班膦酸钠(ibandronate)治疗肺癌转移性骨痛的疗效和安全性。方法:选择2008年1月-2013年1月我院确诊的非小细胞肺癌骨转移患者40例,随机分为A组(首剂负荷剂量组)和B组(首剂常规剂量组)各20例。A组首剂给予负荷剂量,即伊班膦酸钠6mg+0.9%氯化钠100ml静滴15min以上,每天1次,连用3天,以后每4周重复给予1次维持剂量6mg。B组首剂给予常规剂量,即第1天给予伊班膦酸钠6mg+0.9%氯化钠100ml静滴15min以上,第2天及第3天只给予0.9%氯化钠100ml静滴15min以上作为对照,以后剂量及用法同A组。对比分析2组患者的止痛起效时间、止痛维持时间、用药3个周期后的总有效率及不良反应之间的差异。结果:止痛起效时间:A组平均(2.4±1.09)天,B组平均(7.7±1.86)天,差异有统计学意义(P<0.05)。止痛疗效维持时间:A组平均(22.9±8.27)天,B组平均(16.3±3.52)天,差异有统计学意义(P<0.05)。总有效率:A组85%,B组55%,差异有统计学意义(P<0.05)。2组在不良反应发生情况上无统计学差异(P>0.05)。结论:伊班膦酸钠首剂负荷剂量给药止痛起效快,维持时间长,无严重毒副作用,耐受性良好,可明显改善患者转移性骨痛,提高生活质量,是非小细胞肺癌转移性骨痛治疗的一个新选择。Objective：To compare the efficiency and safety of the first agent loading dose and conventional dose ibandronate in the treatment of metastatic bone pain induced by lung cancer. Methods ： Choose 40 cases of non - small cell lung cancer patients with bone metastases between January 2008 and January 2013, randomly divided into group A （the first agent loading dose group） and group B （the first agent conventional dose group） ,20 cases of each. Group A：Ibandronate was given to the patients intravenously at initial loading dose of 6mg for more than 15 min on 3 consec- utive days. Then ibandronate was administered repeatedly at 6mg every 4 weeks. Group B ： The first day to give ibandr- onate intravenously at initial conventional dose of 6 mg for more than 15 min, the second day and third day to give 0.9% sodium chloride 100ml static drop more than 15 min by contrast. Then the dosage was the same with group A. To compare the difference of the initial time of analgesic effect, the persistent time of effect, the total effective rate after 3 cycles and adverse reactions between the two groups. Results： The initial time of effect was （2.4 ± 1.09） dayson average in group A and （7.7 ± 1.86） days on average in group B. There was significant difference between the two groups （P 〈 0.05 ）. The persistent time of effect was （22.9 ±8.27 ） days on average in group A and （ 16.3 ± 3.52） days on average in group B. There was significant difference between the two groups （ P 〈 0.05 ）. The total effective rate was 85% in group A and 55% in group B. There was the significant difference between the two groups （P 〈 0.05 ）. There was no significant difference between the two groups in the adverse reactions （P 〉 0.05 ）. Conclusion： Administration of ibandronate at initial loading dose had quick onset, long persistent time, no more side effects and good tolerance. It could significantly relieve metastasis bone pain and improve the quality of life. Administration of ibandronate at

关 键 词：伊班膦酸钠 非小细胞肺癌 骨转移 骨痛 

分 类 号：R730.53[医药卫生—肿瘤] R734.2[医药卫生—临床医学]